메뉴 건너뛰기




Volumn 19, Issue 7, 2018, Pages 940-952

Correction: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial (The Lancet Oncology (2018) 19(7) (940–952), (S1470204518303516) (10.1016/S1470-2045(18)30351-6));Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(59)  Zhu, Andrew X a,b   Finn, Richard S c   Edeline, Julien d   Cattan, Stephane e   Ogasawara, Sadahisa f   Palmer, Daniel g   Verslype, Chris h   Zagonel, Vittorina i   Fartoux, Laetitia j   Vogel, Arndt k   Sarker, Debashis l   Verset, Gontran m   Chan, Stephen L n   Knox, Jennifer o   Daniele, Bruno p   Webber, Andrea L q   Ebbinghaus, Scot W q   Ma, Junshui q   Siegel, Abby B q   Cheng, Ann Lii r   more..


Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; SORAFENIB; MONOCLONAL ANTIBODY;

EID: 85047827283     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30612-0     Document Type: Erratum
Times cited : (1983)

References (33)
  • 1
    • 84933277181 scopus 로고    scopus 로고
    • Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    • Llovet, JM, Villanueva, A, Lachenmayer, A, Finn, RS, Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12 (2015), 408–424.
    • (2015) Nat Rev Clin Oncol , vol.12 , pp. 408-424
    • Llovet, J.M.1    Villanueva, A.2    Lachenmayer, A.3    Finn, R.S.4
  • 3
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    • Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 4
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 5
    • 85042855944 scopus 로고    scopus 로고
    • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    • Kudo, M, Finn, RS, Qin, S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391 (2018), 1163–1173.
    • (2018) Lancet , vol.391 , pp. 1163-1173
    • Kudo, M.1    Finn, R.S.2    Qin, S.3
  • 6
    • 85038641656 scopus 로고    scopus 로고
    • Systemic therapy for hepatocellular carcinoma: 2017 update
    • Kudo, M, Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology 93:suppl 1 (2017), 135–146.
    • (2017) Oncology , vol.93 , pp. 135-146
    • Kudo, M.1
  • 7
    • 85007560261 scopus 로고    scopus 로고
    • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
    • Bruix, J, Qin, S, Merle, P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
    • (2017) Lancet , vol.389 , pp. 56-66
    • Bruix, J.1    Qin, S.2    Merle, P.3
  • 8
    • 85042883711 scopus 로고    scopus 로고
    • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial
    • Abou-Alfa, GK, Meyer, T, Cheng, AL, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. Proc Am Soc Clin Oncol, 36(suppl 4), 2018, 207.
    • (2018) Proc Am Soc Clin Oncol , vol.36 , pp. 207
    • Abou-Alfa, G.K.1    Meyer, T.2    Cheng, A.L.3
  • 9
    • 85049271441 scopus 로고    scopus 로고
    • Lilly announces CYRAMZA (ramucirumab) phase 3 REACH-2 Study in second-line hepatocellular carcinoma patients met overall survival endpoint
    • (Accessed 25 April 2018)
    • Eli Lilly and Company. Lilly announces CYRAMZA (ramucirumab) phase 3 REACH-2 Study in second-line hepatocellular carcinoma patients met overall survival endpoint. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-cyramzar-ramucirumab-phase-3-reach-2-study, April 4, 2018. (Accessed 25 April 2018)
    • (2018)
  • 10
    • 84949112760 scopus 로고    scopus 로고
    • Immunological landscape and immunotherapy of hepatocellular carcinoma
    • Prieto, J, Melero, I, Sangro, B, Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
    • (2015) Nat Rev Gastroenterol Hepatol , vol.12 , pp. 681-700
    • Prieto, J.1    Melero, I.2    Sangro, B.3
  • 11
    • 57349090407 scopus 로고    scopus 로고
    • Gene expression in fixed tissues and outcome in hepatocellular carcinoma
    • Hoshida, Y, Villanueva, A, Kobayashi, M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008), 1995–2004.
    • (2008) N Engl J Med , vol.359 , pp. 1995-2004
    • Hoshida, Y.1    Villanueva, A.2    Kobayashi, M.3
  • 12
    • 61549122071 scopus 로고    scopus 로고
    • Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
    • Gao, Q, Wang, XY, Qiu, SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15 (2009), 971–979.
    • (2009) Clin Cancer Res , vol.15 , pp. 971-979
    • Gao, Q.1    Wang, X.Y.2    Qiu, S.J.3
  • 13
    • 78650621479 scopus 로고    scopus 로고
    • PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
    • Shi, F, Shi, M, Zeng, Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
    • (2011) Int J Cancer , vol.128 , pp. 887-896
    • Shi, F.1    Shi, M.2    Zeng, Z.3
  • 14
    • 85020894317 scopus 로고    scopus 로고
    • Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing
    • Zheng, C, Zheng, L, Yoo, JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169 (2017), 1342–1356.
    • (2017) Cell , vol.169 , pp. 1342-1356
    • Zheng, C.1    Zheng, L.2    Yoo, J.K.3
  • 15
    • 85018660134 scopus 로고    scopus 로고
    • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    • El-Khoueiry, AB, Sangro, B, Yau, T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.
    • (2017) Lancet , vol.389 , pp. 2492-2502
    • El-Khoueiry, A.B.1    Sangro, B.2    Yau, T.3
  • 16
    • 85049266504 scopus 로고    scopus 로고
    • FDA approves nivolumab for hepatocellular carcinoma
    • (Accessed 28 February 2018)
    • OncLive. FDA approves nivolumab for hepatocellular carcinoma. http://www.onclive.com/web-exclusives/fda-approves-nivolumab-for-hepatocellular-carcinoma, Sept 22, 2017. (Accessed 28 February 2018)
    • (2017)
  • 17
    • 85032439821 scopus 로고    scopus 로고
    • Keytruda (pembrolizumab) prescribing information
    • (Accessed 17 May 2018)
    • Merck Sharp & Dohme. Keytruda (pembrolizumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf, March, 2017. (Accessed 17 May 2018)
    • (2017)
  • 18
    • 84928774156 scopus 로고    scopus 로고
    • The future of immune checkpoint therapy
    • Sharma, P, Allison, JP, The future of immune checkpoint therapy. Science 348 (2015), 56–61.
    • (2015) Science , vol.348 , pp. 56-61
    • Sharma, P.1    Allison, J.P.2
  • 19
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 20
    • 84881128653 scopus 로고    scopus 로고
    • Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
    • Nishino, M, Giobbie-Hurder, A, Gargano, M, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19 (2013), 3936–3943.
    • (2013) Clin Cancer Res , vol.19 , pp. 3936-3943
    • Nishino, M.1    Giobbie-Hurder, A.2    Gargano, M.3
  • 21
    • 84992573817 scopus 로고    scopus 로고
    • Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1
    • Dolled-Filhart, M, Roach, C, Toland, G, et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 140 (2016), 1243–1249.
    • (2016) Arch Pathol Lab Med , vol.140 , pp. 1243-1249
    • Dolled-Filhart, M.1    Roach, C.2    Toland, G.3
  • 22
    • 85049290140 scopus 로고    scopus 로고
    • Clinical utility of the combined positive score for programmed death ligand 1 expression and the approval of pembrolizumab in gastric cancer. Arch Pathol Lab Med (in press).
    • Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand 1 expression and the approval of pembrolizumab in gastric cancer. Arch Pathol Lab Med (in press).
    • Kulangara, K.1    Zhang, N.2    Corigliano, E.3
  • 23
    • 77349102071 scopus 로고    scopus 로고
    • Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
    • Lencioni, R, Llovet, JM, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
    • (2010) Semin Liver Dis , vol.30 , pp. 52-60
    • Lencioni, R.1    Llovet, J.M.2
  • 24
    • 0001072895 scopus 로고
    • The use of confidence or fiducial limits illustrated in the case of binomial
    • Clopper, CJ, Pearson, ES, The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika 26 (1934), 404–413.
    • (1934) Biometrika , vol.26 , pp. 404-413
    • Clopper, C.J.1    Pearson, E.S.2
  • 25
    • 84879141840 scopus 로고    scopus 로고
    • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    • Sangro, B, Gomez-Martin, C, de la Mata, M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
    • (2013) J Hepatol , vol.59 , pp. 81-88
    • Sangro, B.1    Gomez-Martin, C.2    de la Mata, M.3
  • 26
    • 85039166557 scopus 로고    scopus 로고
    • Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses
    • Kelley, RK, Abou-Alfa, GK, Bendel, JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. Proc Am Soc Clin Oncol, 35(suppl 15), 2017, 4073.
    • (2017) Proc Am Soc Clin Oncol , vol.35 , pp. 4073
    • Kelley, R.K.1    Abou-Alfa, G.K.2    Bendel, J.C.3
  • 27
    • 85020908157 scopus 로고    scopus 로고
    • Opdivo (nivolumab) prescribing information
    • (Accessed 17 May 2018)
    • Bristol-Meyers Squibb. Opdivo (nivolumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf, May, 2016. (Accessed 17 May 2018)
    • (2016)
  • 28
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
    • (2015) N Engl J Med , vol.372 , pp. 2509-2520
    • Le, D.T.1    Uram, J.N.2    Wang, H.3
  • 29
    • 84994802263 scopus 로고    scopus 로고
    • Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
    • Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
    • (2016) N Engl J Med , vol.375 , pp. 1823-1833
    • Reck, M.1    Rodríguez-Abreu, D.2    Robinson, A.G.3
  • 30
    • 85042622600 scopus 로고    scopus 로고
    • KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
    • Wainberg, ZA, Jalal, S, Muro, K, et al. KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol, 28(suppl 5), 2017.
    • (2017) Ann Oncol , vol.28
    • Wainberg, Z.A.1    Jalal, S.2    Muro, K.3
  • 31
    • 84939227614 scopus 로고    scopus 로고
    • Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers
    • Carbognin, L, Pilotto, S, Milella, M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10, 2015, e0130142.
    • (2015) PLoS One , vol.10 , pp. e0130142
    • Carbognin, L.1    Pilotto, S.2    Milella, M.3
  • 32
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
    • (2015) N Engl J Med , vol.372 , pp. 2018-2028
    • Garon, E.B.1    Rizvi, N.A.2    Hui, R.3
  • 33
    • 85025439295 scopus 로고    scopus 로고
    • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
    • Overman, MJ, McDermott, R, Leach, JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18 (2017), 1182–1191.
    • (2017) Lancet Oncol , vol.18 , pp. 1182-1191
    • Overman, M.J.1    McDermott, R.2    Leach, J.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.